npj Parkinsons Disease

Papers
(The H4-Index of npj Parkinsons Disease is 51. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Author Correction: Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology317
Subthalamic nucleus in patients with Parkinson’s disease encodes changes and magnitude of applied force189
Investigating the ageing-Parkinson’s disease nexus: standardisation of in vitro models and techniques by the PD-AGE network151
Machine learning integration of serial blood biomarkers enhances cognitive decline prediction in early Parkinson’s disease142
Author Correction: Synaptic loss and its association with symptom severity in Parkinson’s disease131
Cortico-pallidal beta dynamics underlie impaired turning in Parkinson’s disease129
Differences in brain aging between sexes in Parkinson’s disease126
Transformer-based long-term predictor of subthalamic beta activity in Parkinson’s disease123
Classification of Parkinson’s disease and isolated REM sleep behaviour disorder: delineating progression markers from the sebum volatilome113
Push-pull effects of basal ganglia network in Parkinson’s disease inferred by functional MRI104
VisionMD: an open-source tool for video-based analysis of motor function in movement disorders102
Differential memory enrichment of cytotoxic CD4 T cells in Parkinson’s disease patients reactive to α-synuclein98
Cell-to-cell transmitted alpha-synuclein recapitulates experimental Parkinson’s disease95
Corneal confocal microscopy differentiates patients with secondary parkinsonism from idiopathic Parkinson’s disease92
Proinflammatory and GABA eating bacteria in Parkinson's disease gut microbiome from a meta-analysis perspective89
Patient-centered development of clinical outcome assessments in early Parkinson disease: key priorities and advances88
CSF α-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson’s disease88
Alpha synuclein modulates mitochondrial Ca2+ uptake from ER during cell stimulation and under stress conditions87
Physiotherapy interventions for balance impairments in Parkinson’s disease: evidence from a systematic review and dose-response meta-analysis85
Longitudinal non-negative matrix factorization identifies the altered trajectory of motor symptoms in Parkinson’s disease85
Biological aging predicts mortality in Parkinson’s patients: evidence from UK Biobank80
Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease79
Phase II pilot randomized trial of zonisamide for disease modification in prodromal Lewy body disease79
Association between functional gastrointestinal disorders and Parkinson’s disease in a prospective cohort study78
Direct disassembly of α-syn preformed fibrils into α-syn monomers by an all-D-peptide70
Video-based machine learning models for predicting deep brain stimulation outcomes in Parkinson’s disease patients68
Machine learning prediction of discharge destination in patients with Parkinson’s disease; a nationwide cohort study68
Genetic risk and plasma biomarkers of dementia with Lewy bodies in a Chinese population68
Anxiety in synucleinopathies: neuronal circuitry, underlying pathomechanisms and current therapeutic strategies68
Patterns of cerebellar cortex hypermetabolism on motor and cognitive functions in PD68
Targeting the hypothalamic a11 nucleus to treat parkinsonian-like nociceptive impairments65
A systematic exploration of unexploited genes for oxidative stress in Parkinson’s disease64
Unveiling early signs of Parkinson’s disease via a longitudinal analysis of celebrity speech recordings62
Advanced brain aging in Parkinson’s disease with cognitive impairment62
Irisin exhibits neuroprotection by preventing mitochondrial damage in Parkinson’s disease61
The experience of Anxiety for people with Parkinson’s disease61
The pattern of fMRI activation with STN DBS reveals symptom-specific networks61
EGFR phosphorylates DNAJB1 to suppress α-synuclein aggregation in Parkinson’s disease59
The gut microbiome promotes mitochondrial respiration in the brain of a Parkinson’s disease mouse model59
Machine Learning in the Parkinson’s disease smartwatch (PADS) dataset58
The IC-SNc neural circuit mediates prepulse inhibition deficits in MPTP-induced Parkinson’s disease male mice58
Head-to-head comparison of four cerebrospinal fluid and three plasma neurofilament light chain assays in Parkinsonism57
Position paper: leveraging non-human primate (NHP) specificities to accelerate Parkinson’s disease and ageing research57
Does Black vs. White race affect practitioners’ appraisal of Parkinson’s disease?57
Inhibition of T cell infiltration and soluble TNF signaling is neuroprotective in the alpha-synuclein overexpressing mouse model of Parkinson’s disease56
Untargeted serum metabolomics and air pollution in Parkinson’s disease55
Antiviral innate immunity induces alpha synuclein phosphorylation at serine129 in neurons independent of aggregation55
Elevated levels of colonic interleukin-1beta and interleukin-8 in isolated REM sleep behavior disorder without associated changes in permeability55
Mapping the developmental path for Parkinson’s disease therapeutics54
Lrrk2 G2019S mutation incites increased cell-intrinsic neutrophil effector functions and intestinal inflammation in a model of infectious colitis53
JNK3 quantification in plasma: a novel biomarker for neuronal damage in Parkinson’s disease52
Resilience of striatal synaptic plasticity over early structural adaptations in premotor parkinsonism51
Single-cell analysis of the peripheral immune landscape in Parkinson’s disease: insights into dendritic cell and CD4+ T-cell transcriptomics51
In memorium, Michael Zigmond, PhD51
0.08061408996582